Maternal exposure to a high fat diet (HFD) alters milk lipids in lactating women, enhancing adiposity and myeloid inflammation in offspring, even in early life, according to an animal study recently published in Endocrinology. Researchers led by Kanakadurga Singer, MD, and Brigid Gregg, MD, both of the University of Michigan in Ann Arbor, point out...
Bad Reception: Unlocking a Confounding Enigma Behind Monogenic Obesity in Children
When two very different pediatric patients with obesity presented with unusually high leptin levels, endocrine researchers took notice and discovered that leptin was not adequately binding with receptors. When the young patients’ familial history was considered, solutions were finally forthcoming. About three years ago, a 19-month-old girl presented to Sidra Medicine – a women’s and...
Bariatric Surgery Linked to Cardiovascular Improvements in People with Severe Obesity
Bariatric surgery may result in significant cardiometabolic improvements, particularly among younger, female, or white people and those without comorbidities, according to new research published in the Journal of the Endocrine Society. The United States has the highest obesity rates globally. In 2017 – 2018, about 40% of U.S. adults had obesity and 9% had severe obesity. The prevalence is...
Endocrine Society Recommends Bipartisan Solutions to Senate HELP Hearing on Diabetes, Obesity
The Endocrine Society commends the Senate Health, Education, Labor, and Pensions (HELP) Committee for calling attention to the issues that are fueling the diabetes epidemic in its December 14’s hearing and urges the Committee to support bipartisan legislation to begin to address the crisis in our country. More than 38 million Americans have diabetes, and...
FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management
On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who...
Women Face Greater Risk of Obesity in Low- and Middle-Income Countries
Study finds women are 2-3 times more likely to be affected than men Women in low- and middle-income countries, especially in the Sub-Saharan Africa region, may be 10 times more likely to have obesity or heart health issues than their male counterparts, according to a large meta-analysis published in The Journal of Clinical Endocrinology and Metabolism....
Endocrine Society Works to Advance Obesity Legislation in Congress
The Endocrine Society continues to be a vocal advocate to advance legislation that would address prevention and treatment of obesity. In late July, legislation known as the Treat and Reduce Obesity Act (TROA) that the Society endorsed was introduced in the House and the Senate. This important bipartisan legislation would take steps to ensure that...
Obesity Appears to Increase the Risk of Developing Polycystic Ovary Syndrome
Obesity appears to increase the risk of developing polycystic ovary syndrome (PCOS), according to a study presented at ENDO 2023. An estimated 7% to 10% of all reproductive-aged women globally have PCOS. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health, appearance, and fertility. PCOS is associated with health...
